Generation of a high-titer packaging cell line for the production of retroviral vectors in suspension and serum-free media

Gene Therapy

Volumn 14, Issue 24, 2007, Pages 1705-1711

  Ghani, K ^a   Cottin, S ^a   Kamen, A ^b   Caruso, M ^a  

^a LAVAL UNIVERSITY   (Canada)

^b NATIONAL RESEARCH COUNCIL CANADA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

GAG PROTEIN; GREEN FLUORESCENT PROTEIN; POL PROTEIN; RETROVIRUS VECTOR; VIRUS ENVELOPE PROTEIN;

ARTICLE; BIOREACTOR; CELL LINE; CONTROLLED STUDY; CULTURE MEDIUM; EXPRESSION VECTOR; GENE EXPRESSION; GENETIC SELECTION; HUMAN; HUMAN CELL; INTERNAL RIBOSOME ENTRY SITE; MOLECULAR CLONING; MOLONEY LEUKEMIA ONCOVIRUS; NONHUMAN; PRIORITY JOURNAL; SUSPENSION CELL CULTURE; VIRAL GENE DELIVERY SYSTEM; VIRUS PARTICLE; VIRUS RECOMBINANT;

ANIMALS; BIOREACTORS; CELL CULTURE TECHNIQUES; CELL LINE; CULTURE MEDIA, SERUM-FREE; GENE THERAPY; GENETIC ENGINEERING; GENETIC VECTORS; HUMANS; RETROVIRIDAE; TRANSDUCTION, GENETIC; TRANSFECTION;

BOVINAE; MURINAE;

EID: 36949017502     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/sj.gt.3303039     Document Type: Article

References (41)

1. Cavazzana-Calvo M, Hacein-Bey S, de Saint Basile G, Gross F, Yvon E, Nusbaum P et al. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 2000; 288: 669-672.
2. Aiuti A, Slavin S, Aker M, Ficara F, Deola S, Mortellaro A et al. Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science 2002; 296: 2410-2413.
3. Gaspar HB, Parsley KL, Howe S, King D, Gilmour KC, Sinclair J et al. Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector. Lancet 2004; 364: 2181-2187.
4. Sadelain M, Riviere I, Brentjens R. Targeting tumours with genetically enhanced T lymphocytes. Nat Rev Cancer 2003; 3: 35-45.
5. Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, Sherry RM et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 2006; 314: 126-129.
6. Mann R, Mulligan RC, Baltimore D. Construction of a retrovirus packaging mutant and its use to produce helper-free defective retrovirus. Cell 1983; 33: 153-159.
7. Miller AD, Buttimore C. Redesign of retrovirus packaging cell-lines to avoid recombination leading to helper virus production. Mol Cell Biol 1986; 6: 2895-2902.
8. Markowitz D, Goff S, Bank A. A safe packaging line for gene transfer: separating viral genes on two different-plasmids. J Virol 1988; 62: 1120-1124.
9. Markowitz D, Goff S, Bank A. Construction and use of a safe and efficient amphotropic packaging cell line. Virology 1988; 167 400-406.
10. Danos O, Mulligan RC. Safe and efficient generation of recombinant retroviruses with amphotropic and ecotropic host ranges. Proc Natl Acad Sci USA 1988; 85: 6460-6464.
11. Rigg RJ, Chen J, Dando JS, Forestell SP, Plavec I, Bohnlein E. A novel human amphotropic packaging cell line: High titer, complement resistance, and improved safety. Virology 1996; 218: 290-295.
12. Otto E, Jones-Trower A, Vanin EF, Stambaugh K, Mueller SN, Anderson WF et al. Characterization of a replication-competent retrovirus resulting from recombination of packaging and vector sequences. Hum Gene Ther 1994; 5: 567-575.
13. Chong H, Vile RG. Replication-competent retrovirus produced by a 'split-function' third generation amphotropic packaging cell line. Gene Therapy 1996, 3: 624-629.
14. Cosset FL, Takeuchi Y, Battini JL, Weiss RA, Collins MK. High-titer packaging cells producing recombinant retroviruses resistant to human serum. J. Virol 1995; 69: 7436-7436.
15. Forestell SP, Dando JS, Chen J, de Vries P, Bohnlein E, Rigg RJ. Novel retroviral packaging cell lines: Complementary tropisms and improved vector production for efficient gene transfer. Gene Therapy 1997; 4: 600-610.
16. Sheridan PL, Bodner M, Lynn A, Phuong TK, DePolo NJ, de la Vega Jr DJ et al. Generation of retroviral packaging and producer cell lines for large-scale vector production and clinical application: Improved safety and high titer. Mol Ther 2000, 2: 262-275.
17. Zhao Y, Low W, Collins MK. Improved safety and titre of murine leukaemia virus (MLV)-based retroviral vectors. Gene Therapy 2000; 7: 300-305.
18. Yu SS, Kim JM, Kim S. High efficiency retroviral vectors that contain no viral coding sequences. Gene Therapy 2000; 7: 797-804.
19. Tuschong L, Soenen SL, Blaese RM, Candotti F, Muul LM. Immune response to fetal calf serum by two adenosine deaminase-deficient patients after T cell gene therapy. Hum Gene Ther 2002; 13: 1605-1610.
20. Gerin PA, Gilligan MG, Searle PF, Al-Rubeai M. Improved titers of retroviral vectors from the human FLYRD18 packaging cell line in serum- and protein-free medium. Hum Gene Ther 1999; 10: 1965-1974.
21. Gerin PA Searle PF, Al-Rubeai M. Production of retroviral vectors for gene therapy with the human packaging cell line FLYRD18. Biotechnol Prog 1999; 15: 941-948.
22. Glimm H, Flugge K, Mobest D, Hofmann VM, Postmus J, Henschler R et al. Efficient serum-free retroviral gene transfer into primitive human hematopoietic progenitor cells by a defined, high-titer, nonconcentrated vector-containing medium. Hum Gene Ther 1998; 9 771-778.
23. McTaggart S, Al-Rubeai M. Effects of culture parameters on the production of retroviral vectors by a human packaging cell line. Biotechnol Prog 2000; 16: 859-865.
24. Chan LM, Coutelle C, Themis M. A novel human suspension culture packaging cell line for production of high-titre retroviral vectors. Gene Therapy 2001; 8: 697-703.
25. Schilz AJ, Kuhlcke K, Fauser AA, Eckert HG. Optimization of retroviral vector generation for clinical application. J Gene Med 2001; 3 427-436.
26. Budak-Alpdogan T, Przybylowski M, Gonen M, Sadelain M, Bertino J, Riviere I. Functional assessment of the engraftment potential of gammaretrovirus-modified CD34+ cells, using a short serum-free transduction protocol. Hum Gene Ther 2006; 17: 780-794.
27. Kotani H, Newton PBR, Zhang S, Chiang YL, Otto E, Weaver L et al. Improved methods of retroviral vector transduction and production for gene therapy. Hum Gene Ther 1994; 5: 19-28.
28. Pan D, Whitley CB. Closed hollow-fiber bioreactor: A new approach to retroviral vector production. J Gene Med 1999; 1: 433-440
29. Merten OW. State-of-the-art of the production of retroviral vectors. J Gene Med 2004; 6 (Suppl 1): S105-S124.
30. Przybylowski M, Hakakha A, Stefanski J, Hodges J, Sadelain M, Riviere I. Production scale-up and validation of packaging cell clearance of clinical-grade retroviral vector stocks produced in cell factories. Gene Therapy 2006; 13: 95-100~
31. Merten OW, Cruz PE, Rochette C, Geny-Fiamma C, Bouquet C, Goncalves D et al. Comparison of different bioreactor systems for the production of high titer retroviral vectors. Biotechnol Prog 2001; 17: 326-335.
32. Ghani K, Garnier A, Coelho H, Transfiguracion J, Trudel P, Kamen A. Retroviral vector production using suspension-adapted 293GPG cells in a 3L acoustic filter-based perfusion bioreactor. Biotechnol Bioeng 2006; 95: 653-660.
33. Pizzato M, Merten OW, Blair ED, Takeuchi Y. Development of a suspension packaging cell line for production of high titre, serum-resistant murine leukemia virus vectors. Gene Therapy 2001; 8: 737-745.
34. Miller AD, Garda JV, von Suhr N, Lynch CM, Wilson C, Eiden MV. Construction and properties of retrovirus packaging cells based on gibbon ape leukemia virus. J Virol 1991; 65: 2220-2224.
35. Young WB, Link Jr CJ. Chimeric retroviral helper virus and picornavirus IRES sequence to eliminate DNA methylation for improved retroviral packaging cells. J Virol 2000; 74: 5242-5249.
36. Reeves L, Smucker P, Cornetta K. Packaging cell line characteristics and optimizing retroviral vector titer: The National Gene Vector Laboratory experience. Hum Gene Ther 2000; 11: 2093-2103.
37. Kelly PF, Vandergriff J, Nathwani A, Nienhuis AW, Vanin EF. Highly efficient gene transfer into cord blood nonobese diabetic/severe combined immunodeficiency repopulating cells by oncoretroviral vector particles pseudotyped with the feline endogenous retrovirus (RD114) envelope protein. Blood 2000; 96: 1206-1214.
38. Relander T, Brun AC, Olsson K, Pedersen L, Richter J. Overexpression of gibbon ape leukemia virus (GALV) receptor (GLVR1) on human CD34(+) cells increases gene transfer mediated by GALV pseudotyped vectors. Mol Ther 2002; 6: 400-406.
39. Relander T, Johansson M, Olsson K, Ikeda Y, Takeuchi Y, Collins M et al. Gene transfer to repopulating human CD34+ cells using amphotropic-, GALV-, or RD114-pseudotyped HIV-1-based vectors from stable producer cells. Mol Ther 2005; 11: 452-459.
40. Cote J, Garnier A, Massie B, Kamen A. Serum-free production of recombinant proteins and adenoviral vectors by 293SF-3F6 cells. Biotechnol Bioeng 1998; 59: 567-575.
41. Qiao J, Roy V, Girard M-H, Caruso M. High translation efficiency is mediated by the encephalomyocarditis virus IRES if the natural sequence surrounding the 11th AUG is retained. Hum Gene Ther 2002; 13 881-887.